Accelerating time to market, improving clinical outcome in structural heart interventions
Heart valve diseases are on the rise, as is the use of minimally invasive procedures to treat them. Long development cycles in MedTech makes the innovation of new, minimally invasive structural heart devices resource-intensive and challenging.
FEops HEARTguide™ technology uses advanced computational modeling and simulation to provide valve manufacturers and physicians with pre-operative insights into the interaction between patient anatomy and heart valve implants.
The first solution of its kind, FEops HEARTguide™ surpasses basic anatomical measurement, generating accurate predictions of how devices will interact with each unique patient. Our end-to-end solution adds value to optimize and accelerate every step in the structural heart product life cycle, helping manufacturers accelerate time to market and bringing physicians insights that contribute to better patient outcomes.
We help manufacturers accelerate the entire product life cycle and improve clinical outcome for structural heart interventions
FEops HEARTguide™ accelerates R&D processes, and product approval cycles, improves patient selection in clinical trials, and yields better clinical outcomes – benefiting device manufacturers, physicians and patients.
The proprietary predictive simulation technology that drives the FEops HEARTguide™ suite gives device manufacturers tremendous power to accelerate the development of novel minimally invasive structural heart implants. Introduce virtual patients or digital twins into your workflows before making physical prototypes to gain time, cut costs, and test in clinically relevant contexts.
By improving patient selection and optimally preparing physicians for procedures through detailed predictive simulations, FEops HEARTguide™ can accelerate clinical trials and potentially contribute to better patient outcomes.
Make it intuitive for physicians to adopt and endorse novel structural heart devices with FEops HEARTguide™. Inspire confidence and accelerate the learning curve by providing physicians with predictive 3D images that demonstrate how the device will interact with the unique anatomy of each patient – without putting patients at risk.
In going beyond anatomical measurement, only FEops HEARTguide™ provides detailed preoperative insights into the interaction between the implant and the patient’s anatomy. This helps physicians determine optimal implant size and positioning.
With studies estimating the annual number of deaths due to medical errors in the hundreds of thousands, the time has come to revise the way the medical profession gains knowledge and experience. Advances in 3D printing technology and virtual simulation are creating new opportunities to improve the quality of treatments and patient safety.
Have you been in a situation where a generic treatment did not work very well for you or someone you know? Have you ever had that nagging feeling that maybe the doctor (as good as he or she may be) should really be treating YOU rather than a generalized representation of you?
In the US, 1 child in 68 is born with the Autism Spectrum Disorders. Children with Autism have learning and developmental disorders, and represent a number higher than all others disabilities put together. In the US alone, over 6.4% children have special needs in terms of cognitive, motor and sensory processing skills.
The satellite market has been disrupted by the miniaturization of the technology. Lots of small satellites have been created and they aim to provide data for Earth observation, surveillance, telecommunications, smart cities, connectivity, meteorology, emergency responses, ...
According to World Health Organization, 75 Million of people need a wheelchair in the world. But common wheelchair is an obsolete technology. Many situations, both professional and personal, require an adapted mobility, such as:
• People with reduced mobility whose condition requires specific measures and dedicated amenities (adaptation of post, housing, access)
Inaccurate medications kill 5 times more than road accidents in developed countries. Jus in France, they cost 10 billion euros to the public health system. Around the globe, consolidated numbers are not easily accessible but we estimate that inaccurate medications cause at least 1 million deaths and cost 1000 billion dollars to public health systems every year.
The Living Heart Project aims to advance the development of safe and effective cardiovascular products and treatments by uniting engineering, scientific, and biomedical expertise to translate cutting-edge science into improved patient care. Through simulation and the creation of validated models, the project aims to provide personalized, interventional patient care.
Do you think your project is the next big thing?
Join the team !